Treatment of Chronic HCV Infected Egyptian Patients With Electromagnetic Waves and Herbal Therapy
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT02215525|
Recruitment Status : Unknown
Verified July 2014 by Egyptian Military Medical Services.
Recruitment status was: Recruiting
First Posted : August 13, 2014
Last Update Posted : August 13, 2014
|Condition or disease||Intervention/treatment||Phase|
|Hepatitis C||Device: UVA Dietary Supplement: Herbal||Phase 3|
|Study Type :||Interventional (Clinical Trial)|
|Estimated Enrollment :||160 participants|
|Intervention Model:||Parallel Assignment|
|Official Title:||Treatment of Chronic HCV Infected Egyptian Patients With Electromagnetic Waves and Herbal Therapy|
|Study Start Date :||April 2014|
|Estimated Primary Completion Date :||October 2014|
|Estimated Study Completion Date :||May 2015|
Experimental: UVA and Herbal
Twenty four daily one hour sessions using Extra-corporeal electro-magnetic irradiation device combined with Herbal Food Supplement Selenium containing tables as an Anti Oxidant (Tablet A) starting 10 days before the radiation sessions and to continue for 24 weeks
device uses UVA
Other Name: UVA device
Chronic HCV patients, non complicated will be treated by Herbal tablets only . 500 mg twice tablets every 6 hours daily for 6 months.
Dietary Supplement: Herbal
Herbal tablets, 1000 mg every 6 hours daily for 6 months
Other Name: Herbal tablets
- sustained virological response (SVR) at 12 weeks [ Time Frame: 12 weeks after the end of treatment ]SVR is defined as an absence of detectable HCV RNA in the serum with use of an assay with a sensitivity of at least 50 IU/mL.
- Sustained Virological Response (SVR) at 24 weeks [ Time Frame: 24 weeks after completion of the course of treatment. ]Absence of detectable HCV RNA in the serum with use of an assay with a sensitivity of at least 50 IU/mL.
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02215525
|Contact: Tayseer A Abdulaal, M.D.||+email@example.com|
|Cairo, Heliopolis, Egypt, 11613|
|Contact: Tayseer A Abdulaal, M.D. +201223407675 firstname.lastname@example.org|
|Principal Investigator: Tayseer A Abdulaal, M.D.|
|Principal Investigator:||Tayseer A Abdulaal, M.D.||EMMS|